Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

Moderna said on Monday its experimental influenza vaccine was found to be 26.6% more effective than a currently approved ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

Moderna disclosed that a study of 56,000 volunteers older than 50 found its new mRNA flu vaccine was more effective than an ...